Drug Profile
Research programme: topoisomerase I inhibitors - Reata Pharmaceuticals
Alternative Names: HKH 40A; RTA 501; RTA 502Latest Information Update: 12 Oct 2015
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA)
- Developer Reata Pharmaceuticals
- Class Acridines; Naphthalimides
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Feb 2011 No development reported - Preclinical for Cancer in USA (unspecified route)
- 06 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the Cancer pharmacodynamics section
- 19 Apr 2006 This programme is still in active development